Eli Lilly and Co. has announced several leadership changes in the company’s corporate business development, oncology R&D, and managed healthcare services organizations. Darren Carroll (pictured), senior vice president of corporate business development, will retire at the end of August after 22 years of service. Also, Phil Johnson, senior vice president and treasurer, will assume additional duties overseeing merger & acquisition activity, while Heather Wasserman has been promoted to vice president of corporate business development. In addition, Levi Garraway has resigned from his position as senior vice president of oncology research and early phase development. Josh Bilenker will assume those duties in the interim. Also, Frank Cunningham has been promoted to senior vice president of managed healthcare services.
Story Continues Below